We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,986.00
Bid: 11,982.00
Ask: 11,988.00
Change: -38.00 (-0.32%)
Spread: 6.00 (0.05%)
Open: 11,950.00
High: 11,986.00
Low: 11,944.00
Prev. Close: 12,024.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Namibia to start destroying expired vaccines due to slow uptake

Thu, 25th Nov 2021 12:12

By Nyasha Nyaungwa

WINDHOEK, Nov 25 (Reuters) - Namibia has warned that more
than 268,000 doses of AstraZeneca and Pfizer
COVID-19 vaccines are at risk of being destroyed, some as early
as next week, due to a slow uptake by citizens.

Ben Nangombe, executive director in the health ministry,
told Reuters on Thursday that 52,261 AstraZeneca vaccines will
expire on Tuesday next week, while 215,996 Pfizer shots will be
destroyed in January and February if they find no takers as
vaccine hesitancy rises.

Namibia, which has started vaccinating 12- to 17-year olds
with the Pfizer vaccine after the WHO said on Nov. 15 that it is
suitable for people in that age group, has 809,414 doses
available nationally.

The southern African nation recorded 15 new cases on Tuesday
to bring the number of active cases to 85 compared to a peak of
2,547 cases in a single day on June 24.

Only 298,503, or 20% of an estimated eligible population of
1.5 million, have been fully vaccinated in Namibia, with the
Chinese-made Sinopharm vaccine the most used after 145,483
people received two doses since the country’s vaccination
programme started in March.

The Russian-made Sputnik V vaccine has been used the least,
with only 71 people fully vaccinated before its rollout was
suspended on Oct. 23, days after the drugs regulator in
neighbouring South Africa flagged concerns about its safety for
people at risk of HIV.

South African health regulator SAHPRA decided against
approving an emergency use application for Sputnik V after some
studies suggested vaccines using the Adenovirus Type 5 vector -
which Sputnik V does - can lead to higher susceptibility to HIV
in men.

South Africa and Namibia have high HIV prevalence rates.
(Reporting by Nyasha Nyaungwa; editing by Wendell Roelf and
Giles Elgood)

More News
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more
25 Apr 2024 07:56

REPEAT: Miner Anglo American reviews takeover bid from rival BHP

(Alliance News) - Stocks in London are called to open slightly higher, after a busy start to the day, with corporate earnings and updates.

Read more
25 Apr 2024 07:52

Sanofi profit slips on generic competition and currency effects

April 25 (Reuters) - Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.